Edgar Filing: ACORDA THERAPEUTICS INC - Form 4

ACORDA 7 Form 4 March 04, 2	THERAPEUTICS	INC	5									
FORM	ΠΔ										APPROV/	۹L
	UNITED	STATES		RITIES A				NGE	COMMISSIO	N OMB Number:	3235	-0287
Check the if no lor subject Section Form 4	nger STATEN 16.									Estimated burden ho	Expires: January 3 200 Estimated average burden hours per response 0	
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities E Section 17(a) of the Public Utility Holding Company 30(h) of the Investment Company Ac							y Act	of 1935 or Secti			0.0	
(Print or Type	Responses)											
1. Name and Address of Reporting Person <u>*</u> Blight Andrew			2. Issuer Name and Ticker or Trading Symbol					-	5. Relationship of Reporting Person(s) to Issuer			
		ACORDA THERAPEUTICS INC [ACOR]						(Check all applicable)				
(Last) 420 SAW 1		3. Date of Earliest Transaction (Month/Day/Year) 03/02/2016						Director 10% Owner X Officer (give title Other (specify below) below) Chief Scientific Officer				
	4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person							
ARDSLEY		For Person						Form filed by More than One Reporting n				
(City)	(State)	(Zip)	Tab	le I - Non-	-De	rivative	Secur	ities A	cquired, Disposed	of, or Beneficia	ally Owne	d
1.Title of Security (Instr. 3)	2. Transaction Date 2A. Deeme (Month/Day/Year) Execution I any (Month/Da		Date, if	3. 4. Securities ate, if TransactionAcquired (A) or Code Disposed of (D) Year) (Instr. 8) (Instr. 3, 4 and 2) (A)				5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect Beneficia	Beneficial Ownership	
				Code V	Ā	Amount	or (D)	Price	Transaction(s) (Instr. 3 and 4)			
Reminder: Re	port on a separate line	e for each cla	iss of sec	urities bene	efic	ially ow	ned dii	rectly of	or indirectly.			
						inforn requi	natior red to ays a (n cont respo	pond to the colle ained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

Edgar Filing: ACORDA THERAPEUTICS INC - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr.		Acquired (or Dispose (D) (Instr. 3, 4, and 5)	d of				
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	\$ 35.53	03/02/2016		А		20,300		<u>(1)</u>	03/02/2026	Common Stock	20,300

Reporting Owners

Reporting Owner Name / Addro	255	Relationships								
F8	Director	10% Owner	Officer	Other						
Blight Andrew 420 SAW MILL RIVER ROA ARDSLEY, NY 10502	AD		Chief Scientific Officer							
Signatures										
/s/ Andrew (Blight)3/04/2016									

<u>**</u>Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares subject to this option vest in equal quarterly installments over four years beginning on January 1, 2016 with the first quarterly installment vesting on April 1, 2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.